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CLINICAL INVESTIGATION
Recurrent Measurement of Frailty Is Important for Mortality
Prediction: Findings from the North West Adelaide Health Study
Mark Q. Thompson, MPH,*† Olga Theou, PhD,*†‡ Graeme R. Tucker, PhD,†
Robert J. Adams, PhD,§ and Renuka Visvanathan, PhD*†
OBJECTIVES: Frailty places individuals at greater risk of
adverse health outcomes. However, it is a dynamic condition
and may not always lead to decline. Our objective was to
determine the relationship between frailty status (at baseline
and follow-up) and mortality using both the frailty pheno-
type (FP) and frailty index (FI).
DESIGN: Population-based cohort.
SETTING: Community-dwelling older adults.
PARTICIPANTS: A total of 909 individuals aged 65 years
or older (55% female), mean age 74.4 (SD 6.2) years, had
frailty measurement at baseline. Overall, 549 participants
had frailty measurement at two time points.
MEASUREMENTS: Frailty was measured using the FP and
FI, with a mean 4.5 years between baseline and follow-up.
Mortality was matched to official death records with a min-
imum of 10 years of follow-up.
RESULTS: For both measures, baseline frailty was a signifi-
cant predictor of mortality up to 10 years, with initially good
predictive ability (area under the curve [AUC] = .8-.9) decreas-
ing over time. Repeated measurement at follow-up resulted in
good prediction compared with lower (AUC = .6-.7) discrimi-
nation of equivalent baseline frailty status. In a multivariable
model, frailty measurement at follow-up was a stronger pre-
dictor of mortality compared with baseline. Frailty change for
the Continuous FI was a significant predictor of decreased or
increased mortality risk based on corresponding improvement
or worsening of score (hazard ratio = 1.04; 95% confidence
interval = 1.02-1.07; P = .001).
CONCLUSIONS: Frailty measurement is a good predictor
of mortality up to 10 years; however, recency of frailty
measurement is important for improved prediction. A regu-
lar review of frailty status is required in older adults. J Am
Geriatr Soc 00:1-7, 2019.
Key words: frailty; Australia; mortality; longitudinal
study; older adults
Frailty represents a state of decreased physiologic reservethat places individuals at a greater risk of adverse out-
comes such as disability, institutionalization, and death.1,2
Despite the negative perceptions associated with frailty, it is
possible for frailty status to improve or to remain stable
over time.3,4 This finding is pertinent because interventions
exist that may slow or reverse the frailty process.1,5 The
routine assessment of the frailty status of older adults has
been highlighted as a key activity in primary care so these
interventions might be offered in a timely manner.6-8
The two main approaches to describing frailty are the
frailty phenotype (FP) that defines frailty as a biological
syndrome based on five physical variables,9 and the accu-
mulation of deficit approach that represents the proportion
of deficits present across a range of systems and is represen-
ted as a frailty index (FI).10 A number of studies examined
the relationship between frailty and mortality, and they
identified that when compared with non-frail individuals,
those classified as frail by either the FP or FI have a greater
risk of death.2,11-14 The method of frailty measurement has
an impact on both frailty prevalence and mortality risk, with
the more encompassing definition of the FI generating a
higher prevalence.2 Additionally, there is a cumulative effect
where the presence of an increased number of deficits is asso-
ciated with greater mortality risk.13
Frailty was identified as a significant long-term predictor
of mortality, with predictive strength best over a shorter
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follow-up,2 potentially due to the dynamic nature of frailty
where change is likely over time.12 The relationship between
change in frailty classification and mortality was explored in
single studies for the FP15 and the FI.16 Although clinicians
increasingly recognize the need for assessing frailty status,8
review of frailty status following intervention requires just as
much attention. Understanding the relationship between chang-
ing frailty status and mortality may help provide the evidence
base that clinicians need to be convinced that both assessment
and review of frailty status may be of benefit to their patients.
The aim of this study was to examine the predictive
ability of frailty classification on mortality over 10 years
and the effect of recency of frailty measurement (at follow-
up 4.5 y later) on mortality prediction for both the FP and
FI in the North West Adelaide Health Study (NWAHS).
METHODS
Sample
This study is a secondary analysis of the NWAHS, a longitudi-
nal population survey consisting of community-dwelling adults
randomly selected from households in the northwest region of
metropolitan Adelaide.17 Participants attended a clinic and
completed a written and telephone survey for each study stage.
Because the probability of selection was known, data were
weighted to the area population. The South Australia Health
Human Research Ethics Committee (reference no. HREC/15/
TQEH/61) provided ethics approval for this study.
The baseline cohort of this study included participants
aged 65 years or older who completed stage 2 (2004-2006)
(baseline). We excluded participants who had a FP score with
fewer than three valid responses or a FI with fewer than
27 (20% missing) valid responses at baseline. To examine
the effect of recency of frailty measurement, we analyzed a
returning sample of participants who attended both stage 2
(baseline) and stage 3 (2008-2010) (follow-up) with the same
exclusion criteria for FP and FI valid responses as at baseline.
Participant mortality information was drawn from data mat-
ched to official death records and used to calculate number of
years survived from follow-up, with all participants having a
minimum of 10 years of follow-up from baseline.
Frailty Phenotype
A modified FP was used in this study with identical variables
used at baseline and follow-up (Table S1). Three iterations of
the FP were used: a Continuous FP; a 5-Category FP (0 char-
acteristics, 1 characteristic, 2 characteristics, 3 characteristics,
4-5 characteristics); and a 3-Category FP (individuals with
three or more characteristics were classified as frail; those
with one or two characteristics were classified as pre-frail;
and those with no characteristics present were non-frail).9
The modified FP used in NWAHS was described previ-
ously.18 Although the FP was originally designed as a cate-
gorical variable, it has been used in continuous form.18,19
Frailty Index
We developed a 34-item FI following a standard methodol-
ogy20 (Table S1). Three iterations of the FI were used: a Con-
tinuous FI; a 10% Increment FI (0-10%, 10-20%, 20-30%,
30-40%, 40-50%, and >50% proportion of deficits); and a
3-Category FI (>.21 proportion of deficits = frail; .10 and
.21 = pre-frail; and <.10 non-frail). The FI used in NWAHS
was described previously.18
Data Analysis
We used SPSS v.23 software (IBM Corp, Armonk, NY) for
all statistical analysis. Cohort case weights were used in anal-
ysis and for reporting percentages to ensure the sample was
representative of the population of North West Adelaide.
Weighting was rescaled to sum to the sample size for the
returning sample to adjust for attrition. An α value of .05
was used for determining statistical significance. Participants
in the cohort were matched against death records to deter-
mine the time of death. All-cause mortality was analyzed.
Descriptive characteristics and the number and proportion
of participants classified as non-frail, pre-frail, and frail were
reported according to mortality rate at 1, 2, 4, 6, 8, and
10 years from baseline. State transitions including participants
lost to follow-up were reported. Complex samples procedures
were used in SPSS to allow for the effect of the sample design
on the standard error of estimates. We performed significance
testing of cross-tabs using a Pearson χ2 test and tests for lin-
ear by linear association. Survival was modeled using com-
plex samples Cox regression to allow for the design of the
sample, and we reported the hazard ratio. Multivariable anal-
ysis included combined frailty classification at baseline and
follow-up, sex, age group, education level, and income level.
A predictive probability of surviving 1, 2, 4, 6, 8 and 10 years
from baseline was generated through logistic regression to
generate an area under the curve (AUC) value for frailty clas-
sification at baseline as well as at follow-up.
RESULTS
This study included 909 participants (mean age = 74.4 [SD 6.2]
y; 55% female) at baseline (Table 1). We excluded 36 partici-
pants from analysis at baseline due to insufficient FI or FP
variables. For the returning cohort analysis, we included
549 participants who had frailty measurement at both stages
2 and 3. Of those excluded from the returning cohort,
147 had died between baseline and follow-up, and a further
213 were either lost to follow-up or had insufficient FI or FP
variables. The 360 participants excluded from the returning
cohort were significantly more likely to be older (mean
age = 76.9 [SD 6.2] y), have lower income status, and higher
baseline frailty prevalence (FP = 29.1% frail; FI = 62.0%
frail) than the whole sample (Table S2). All participants at
baseline had a minimum of 10 years of survival data.
Over a 10-year period, 292 (33.8%) participants died,
with men having significantly higher mortality rates (40.1%)
compared with their female counterparts (28.6%) (Table 1,
Figure 1, and Table S3). Likewise, for older age group, 10-year
mortality for those aged 75 years or older (54.3%) was signifi-
cantly higher than for those aged 65 to 74 years (17.8%).
Low-income category was also significantly associated with
mortality at the 10-year mark, at 35.5% for the lowest income
group compared with 11.6% for the higher group.
The 3-Category FP classified 18.3% of participants as
frail at baseline; 48.1% were frail according to the 3-Category
FI. Mortality was significantly higher for increasing levels of
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frailty for both the FP and FI. For the 3-Category FP, 60.2%
of individuals classified as frail had died at 10 years compared
with 26.3% of those who were non-frail. Of those classified
as frail by the 3-Category FI, 45.1% had died at 10 years, in
comparison with 21.4% of non-frail individuals. Frailty state
transitions for this cohort are presented in Table S4 and were
discussed in detail elsewhere.4
FP and FI classification at baseline significantly
predicted the probability of surviving 1, 2, 4, 6, 8, and
10 years from baseline (Table 2) through AUC analysis.
Mortality prediction was strongest at 1 year with good dis-
crimination (AUC = .8-.9) for all iterations of FP and FI
measures: All iterations retained acceptable discrimination
(AUC = .7-.8) at 2 and 4 years and low (AUC: .6-.7) but
significant prediction of mortality at 6, 8, and 10 years.
Repeated frailty measurement at follow-up, for the
returning cohort of 563 participants, resulted in good dis-
criminative ability for all iterations of the FP and FI at 6, 8,
and 10 years from baseline (that equates to approximately
2, 4, and 6 years post follow-up), compared with low dis-
crimination for equivalent baseline measurement (Table 2).
In a multivariable model that included frailty status at
both baseline and follow-up for the returning sample of
563 participants, frailty measurement at follow-up, but not at
baseline, was significantly associated with mortality for all
iterations of the FP and the 3 Category FI; however, both
time points were significant for the Continuous FI and the
10% Increment FI (Table 3). The significant negative coeffi-
cient for the latter measures at baseline is a masked result due
to possible suppression by the stronger predictor at follow-
up. Addressing this by including frailty change (Continuous
FI: follow-up minus baseline) in the model, each 1% improve-
ment or worsening in the Continuous FI was associated
with a corresponding 4% significant increase or decrease,
respectively, in mortality risk (hazard ratio [HR] = 1.04; 95%
confidence interval [CI] = 1.02-1.07; P = .001). The Continu-
ous FI at follow-up remained a significant mortality predictor
in this model. Analysis of the returning sample examining
baseline and follow-up frailty classification separately illus-
trated the stronger association between follow-up frailty mea-
surement and mortality in comparison with baseline
measurement (Tables S5, S6, and S7).
Compared with a reference category of 0 characteristics,
significant elevated mortality risk was identified at three
characteristics for the 5-Category FP at follow-up (HR =
2.97; 95% CI = 1.33-6.63; P = .008). For the 10% incre-
ment FI, with a reference category of 0% to 10%, a margin-
ally significant elevation of mortality risk was observed for a
10% to 20% proportion of deficits at follow-up (HR = 2.55;
95% CI = 1.00-6.46; P = .49), and significant for the 20%
to 30% proportion (HR = 4.82; 95%CI = 1.83-12.69;
P = .002). HRs at higher proportions of characteristics/defi-
cits increased exponentially and were highly significant for
both the FP and FI.
DISCUSSION
Frailty classification was a significant predictor of mortality
up to 10 years in this cohort of community-dwelling
Australian older adults, with predictive ability strongest
immediately after measurement and gradually decreasing
over time. Mortality prediction was improved by repeated
frailty measurement at follow-up.
Approximately one-third of participants died over
10 years, with mortality significantly higher for men, those
in the older age group (≥75 y), and those on the lowest
income group (<$20 000 per annum), consistent with other
studies.2,12,21
Table 1. Descriptive Characteristics of Sample at Baseline and Frailty Status for the Frailty Phenotype and Frailty
Index
Whole sample
3-Category FP, n (%) 3-Category FI, n (%)
n (%) Non-frail Pre-frail Frail Non-frail Pre-frail Frail
909 289 (30.1) 470 (51.6) 150 (18.3) 211 (21.5) 285 (30.4) 413 (48.1)
Sex
Male 453 (45.2) 165 (36.5) 229 (50.2) 59 (13.3)* 124 (27.0) 151 (34.1) 178 (38.9)*
Female 456 (54.8) 124 (24.8) 241 (57.2) 91 (22.5) 87 (16.9) 134 (27.4) 235 (55.7)
Age groups, y
65-74 554 (56.3) 204 (35.7) 295 (53.4) 55 (10.8)* 147 (26.1) 192 (33.9) 215 (40.0)*
≥75 355 (43.7) 85 (22.8) 175 (49.2) 95 (28.0) 64 (15.5) 93 (25.9) 198 (58.5)
Education levela
Up to secondary 569 (63.5) 159 (26.9) 308 (52.9) 102 (20.3)* 110 (17.8) 190 (33.3) 269 (48.9)*
Trade/Certificate/Diploma 288 (30.6) 115 (37.0) 133 (49.0) 40 (14.0) 87 (28.1) 80 (25.3) 121 (46.6)
≥Bachelor’s degree 25 (2.5) 13 (58.2) 10 (32.9) 2 (8.9) 10 (41.6) 10 (38.4) 5 (19.9)
Income groupsa
Up to $20 k 462 (46.5) 117 (23.1) 254 (55.5) 91 (21.4)* 81 (15.6) 144 (30.1) 237 (54.3)*
$20-$40 k 281 (33.5) 117 (41.2) 129 (44.6) 35 (14.2) 87 (29.1) 93 (32.3) 101 (38.6)
$40-$60 k 59 (6.8) 29 (43.6) 24 (45.3) 6 (11.1) 21 (33.1) 17 (30.4) 21 (36.5)
>$60 k 26 (2.6) 13 (47.1) 12 (49.4) 1 (3.5) 11 (36.8) 10 (39.1) 5 (24.2)
Abbreviations: FI, frailty index; FP, frailty phenotype.
Note: n, unweighted; % reported using cohort case weights. The 3-Category FP, no. of characteristics: 0, non-frail; 1-2, pre-frail, ≥3, frail; 3-Category FI, pro-
portion of deficits: 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
*P < .05 (main effects reported).
aMissing nor included.
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We examined various iterations of the FP (Continuous,
5-Category, and 3-Category) and the FI (Continuous, 10%
Increment, and 3-Category) with 18.3% of individuals clas-
sified as frail by the 3-Category FP and 48.1% by the
3-Category FI. Both frailty measures in all their iterations
demonstrated significant discriminative ability in predicting
mortality over 10 years, with AUC prediction initially excel-
lent (AUC = .8-.9), decreasing incrementally over time to
low (AUC = .6-.7).22 Frailty measurement for all iterations
of the FP and FI at follow-up had excellent discriminative
ability for mortality, compared with the low AUC of
corresponding baseline measurements. This finding is con-
sistent with the literature, where the strongest association
with mortality is immediately after the frailty measurement,
remaining predictive up to 11 years.2 These findings are
likely due to the dynamic nature of frailty where individuals
are more likely to worsen with increasing age; hence mor-
tality prediction is better over shorter follow-up periods.12
When we examined each iteration of the FP and the FI
in multivariable analysis that included both baseline and
follow-up measurement, frailty measurement at follow-up,
but not at baseline, was significantly associated with mortal-
ity for all iterations of the FP and the 3-Category FI; mea-
surements at both time points were significant for the
Continuous FI and 10% Increment FI. The separate analysis
of the returning sample also illustrated the stronger associa-
tion of follow-up measurement, countering the effect of bias
of being more likely to lose those who were frail at baseline.
Frailty change (between baseline and follow-up) for the
Continuous FI was a significant predictor of decreased or
increased mortality risk in this study based on corresponding
improvement or worsening of frailty, consistent with the
Figure 1. Mortality rates (proportion dead) over 10 years by baseline frailty status for the frailty phenotype (FP) and frailty index
(FI). Proportions reported using cohort case weights. Error bars represent 95% confidence intervals. Note: 3-Category FP, no. of
characteristics present: 0, non-frail; 1-2, pre-frail, ≥3, frail; 5-Category FP, no. of characteristics present: 0, 1, 2, 3, 4-5; 3-Category
FI, proportion of deficits: 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail; 10% Increment FI: 0%-10%, 10%-20%, 20%-
30%, 30%-40%, 40%-50%, >50%.
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findings of Chamberlain and colleagues.16 Although not sig-
nificant in this study, worsening of FP status was identified
elsewhere with increased mortality risk.15 The FI was
described as being more sensitive to change and having more
precise mortality risk prediction compared with the FP due
to its more comprehensive nature.12,16
The findings of our research for the FP were consistent
with those of the original FP study in which three character-
istics was identified as a significant cut point for elevated
mortality risk,9 and furthermore, that each increase in the
number of FP characteristics is associated with elevated
mortality risk.23
However, our finding that those classified as frail by
the 3-Category FP at follow-up had over triple the mortality
risk compared with those who were non-frail was slightly
higher than that of a systematic review by Chang and Lin11
(pooled HR = 2.00) but was within the range of included
studies. The FP has good predictive ability of mortality, and
with only five variables for measurement, this approach is
clinically feasible but limited in terms of the scope of char-
acteristics measured compared with the FI.23
Likewise, our findings for the FI reflected those of other
studies that demonstrated a dose-response relationship
between higher proportions of FI deficits of worse sur-
vival.10,14,24,25 In this study, the 7% increase in mortality
risk for each 1% increase in proportion of deficits at follow-
up for the Continuous FI was higher than the pooled risk of
4% per 1% increase in FI described in a systematic review
by Kojima and colleagues.12 However, it was within the
upper range of studies included in that review. The FI was
described as both pragmatic and flexible in terms of frailty
measurement, and its graded system of measurement as valu-
able in providing a more sensitive risk prediction for adverse
health outcomes.12,25 The higher mortality rates for the FP
and FI in this study may be associated with the lower socio-
economic status (SES) of the NWAHS region compared with
the Australian population.26 The use of routinely collated
data from electronic health records in both the primary care
and acute settings are likely to enhance the feasibility of
automated repeat measurements of frailty,27,28 and evolving
wearable technologies may provide real-time data on the
dynamic nature of the frailty syndrome.29,30 These develop-
ments call for a new generation of dynamic frailty studies.
Strengths of this study were the use of population-based
data for both the FP and FI, and 10 years of follow-up mat-
ched to official death records. Limitations of this study
included a lack of some aging-specific variables such as walk-
ing speed or cognitive impairment in the data set, the use of
a modified FP, and the lower SES of the NWAHS in compar-
ison with the broader Adelaide metropolitan area. Addition-
ally, the inclusion of only community-dwelling participants
in this study, and the exclusion of 360 participants from the
returning cohort who were more likely to be older, have
lower income status, and higher baseline frailty prevalence
than those included, is likely to have resulted in an underesti-
mation of frailty prevalence at baseline and follow-up, and it
may have weakened the mortality prediction for frailty at
follow-up. Furthermore, the 4.5-year interval between base-
line and follow-up allows the effect of time to become more
evident with participants in the returning sample more likely
Table 2. Discriminative Ability of Frailty Phenotype and Frailty Index at Baseline and at Follow-up for Predicting
Mortalitya
Whole sample (n = 909)
AUC (95% CI)
1 y 2 y 4 y 6 y 8 y 10 y
FP at baseline
Model 1: Continuous FP .87 (.81-.94)* .78 (.71-.85)* .73 (.68-.79)* .68 (.63-.73)* .66 (.62-.71)* .67 (.62-.71)*
Model 2: 5-Category FP .87 (.80-.93)* .78 (.71-.85)* .73 (.68-.80)* .69 (.64-.74)* .67 (.63-.72)* .67 (.63-.71)*
Model 3: 3-Category FP .85 (.77-.93)* .77 (.69-.84)* .71 (.66-.78)* .68 (.63-.73)* .67 (.62-.71)* .66 (.62-.71)*
FI at baseline
Model 4: Continuous FI .83 (.74-.92)* .76 (.69-.84)* .73 (.67-.79)* .68 (.63-.73)* .65 (.61-.70)* .66 (.62-.70)*
Model 5: 10% Increment FI .82 (.73-.92)* .79 (.72-.86)* .76 (.71-.81)* .71 (.66-.76)* .68 (.64-.73)* .68 (.64-.72)*
Model 6: 3-Category FI .80 (.70-.90)* .75 (.68-.83)* .73 (.68-.79)* .70 (.65-.74)* .68 (.64-.72)* .68 (.64-.72)*
Returning sample (n = 549) b
FP at follow-up 1.6 yc 3.6 yc 5.6 yc
Model 1: Continuous FP - - - .85 (.80-.91)* .82 (.76-.88)* .80 (.74-.85)*
Model 2: 5-Category FP - - - .88 (.83-.94)* .84 (.78-.90)* .80 (.75-.85)*
Model 3: 3-Category FP - - - .87 (.83-.91)* .83 (.77-.88)* .79 (.73-.84)*
FI at follow-up
Model 4: Continuous FI - - - .87 (.82-.92) * .82 (.77-.87)* .80 (.75-.85)*
Model 5: 10% Increment FI - - - .87 (.82-.92)* .85 (.80-.89)* .81 (.76-.86)*
Model 6: 3-Category FI - - - .85 (.80-.89)* .83 (.78-.87)* .80 (.75-.85)*
Abbreviations: AUC, area under the curve; FI, frailty index; FP, frailty phenotype.
Note: 5-Category FP, no. of characteristics: 0, 1, 2, 3, 4-5; 3-Category FP, no. of characteristics: 0, non-frail; 1-2, pre-frail, ≥3, frail; 10% Increment FI: 0%-
10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, >50%; 3-Category FI (proportion of deficits): 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
*P < .001.
aAUC for years survived from baseline. Adjusted for age, sex, education, and income. Follow-up mean = 4.5 years.
bAUC for the returning sample at follow-up is based on survival years from baseline.
cMean years between follow-up measurement and survival years from baseline.
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to have higher levels of frailty at follow-up, which is to be
expected for an aging cohort. Additionally, the Continuous
FP is an ordinal measure that does not fulfill the precondi-
tions of most parametric statistical tests; however, nearly all
articles treat this as a continuous measure, as we have done.
In conclusion, this study identified that recency of frailty
measurement is important for predicting survival. Although
frailty measurement was a significant predictor of mortality
risk up to 10 years, recency of measurement was a stronger
predictor. Routine assessment of frailty in older adults was
highlighted as important in the clinical setting,7,8 which can
feasibly be measured using routinely collected data.6,27,28 The
findings from this study have implications for the clinical set-
ting where a more recent frailty assessment is likely to provide
the best information about the health status of older adults,
taking into account the dynamic nature of the frailty condition
and that regular reevaluation is necessary to keep this frailty
profile up to date.
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Non-frail (n = 207) 1 - 1 -
Pre-frail (n = 288) .90 (.53-1.55) .713 1.28 (.69-2.37) .426
Frail (n = 54) 1.16 (.55-2.43) .696 3.35 (1.65-6.79) .001*
FI
Model 4: Continuous FI per .01 score .96 (.94-.98) <.001* 1.07 (1.04-1.09) <.001*
Model 5: 10% increment FI
0%-10% (n = 160) 1 - 1 -
10%-20% (n = 177) .62 (.31-1.24) .178 2.55 (1.00-6.46) .049*
20%-30% (n = 106) .63 (.29-1.40) .261 4.82 (1.83-12.69) .002*
30%-40% (n = 59) .46 (.18-1.18) .105 5.53 (1.92-15.95) .002*
40%-50% (n = 36) .31 (.10-.98) .047* 9.52 (3.16-28.69) <.001*
>50% (n = 11) .30 (.06-1.51) .144 21.62 (6.11-76.47) <.001*
Model 6: 3-Category FI
Non-frail (n = 160) 1 - 1 -
Pre-frail (n = 191) .67 (.34-1.33) .251 2.42 (.95-6.15) .063
Frail (n = 198) .72 (.35-1.49) .373 6.08 (2.38-15.57) <.001*
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; FI, frailty index; FP, frailty phenotype.
Note: 5-Category FP, no. of characteristics: 0, 1, 2, 3, 4-5; 3-Category FP, no. of characteristics: 0, non-frail; 1-2, pre-frail, ≥3, frail; 10% Increment FI: 0%-
10%, 10%-20%, 20%-30%, 30%-40%, 40%-50%, >50%; 3-Category FI, proportion of deficits: 0 to ≤.10, non-frail; >.10 to ≤.21, pre-frail; >.21, frail.
The follow-up window for mortality was from study entry over the period 2004-2006 to a censoring date of September 30, 2016 (minimum of 10 y of mor-
tality data for all participants).
*P < .05.
aWeighted multivariable analysis adjusted for frailty at both time points, age, sex, education, and income.
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